Form 4: Zymeworks CEO Galbraith Reports RSU Vesting, Tax-Related Stock Sale

Zymeworks Inc. Chair & CEO Kenneth Galbraith reported the vesting of 100,000 restricted stock units and a subsequent non-discretionary sale of 47,528 shares to cover tax obligations.

Summary

• Kenneth Galbraith, Chair & CEO of Zymeworks Inc. (ZYME), reported transactions on December 22, 2025.
• Acquired 100,000 shares of common stock upon the vesting of Restricted Stock Units (RSUs) granted on December 22, 2022, at a price of $0.00.
• Subsequently sold 47,528 shares of common stock at a weighted average price of $27.0222.
• The sale was explicitly stated as non-discretionary, solely to cover tax withholding obligations and other applicable fees pursuant to mandatory "sell to cover" provisions.
• Following these transactions, Mr. Galbraith beneficially owns 133,275 shares of Zymeworks common stock directly.
• All 100,000 Restricted Stock Units have vested and are no longer beneficially owned as derivative securities.

Sentiment

Score: 6

Explanation: The filing details a routine executive compensation event involving the vesting of Restricted Stock Units and a mandatory, non-discretionary sale of shares to cover tax obligations. This is a standard practice and does not indicate any change in company fundamentals or management's outlook, leading to a largely neutral sentiment with a slight positive tilt due to the successful compensation event for the executive.

Positives

• The vesting of 100,000 Restricted Stock Units indicates a successful compensation event for the CEO.
• The sale of shares was explicitly stated as non-discretionary and solely for covering tax withholding obligations, not a voluntary divestment, which typically does not signal a lack of confidence in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or strategic outlook.

Management Comments

• The Reporting Person did not sell or otherwise dispose of any of the shares reported on this Form 4 for any reason other than to cover required taxes and fees.

Industry Context

This Form 4 filing details a routine insider transaction related to executive compensation and tax obligations, which is common across all industries for publicly traded companies. It does not provide specific insights into broader industry trends or competitive landscape for Zymeworks Inc.

Stakeholder Impact

• Shareholders: The transaction is a routine insider compensation event and tax-related sale, which typically has minimal direct impact on existing shareholders. It does not signal a change in management's confidence or company fundamentals.
• Employees: No direct impact on employees is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details a routine, non-discretionary transaction by the CEO related to the vesting of Restricted Stock Units and subsequent tax obligations. It does not provide new information regarding the company's operational performance, strategic direction, or financial health that would warrant a change in investment recommendation. Investors should maintain their current position based on broader company fundamentals and market conditions.

Keywords

Zymeworks, ZYME, Kenneth Galbraith, Insider Transaction, Form 4, RSU Vesting, Stock Sale, CEO, Beneficial Ownership